Targeting a specific enzyme to prevent abnormal bone growth
Targeting jmjd3 mitigates heterotopic ossification
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11037879
This study is looking at how a specific enzyme called JMJD3 might help stop the unusual growth of bone in soft tissues after injuries, like burns or surgeries, and aims to find new ways to treat people who experience this condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11037879 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting the enzyme JMJD3 can help prevent heterotopic ossification (HO), which is the abnormal formation of bone in soft tissues following injuries like burns or surgeries. The study aims to understand the molecular mechanisms that lead to HO, particularly focusing on the role of inflammatory signals and specific cell types involved in this process. By using both human cells and animal models, the researchers will explore how manipulating these pathways can stop the progression of HO, potentially leading to new treatment options for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have experienced hip arthroplasty, burns, or musculoskeletal injuries and are at risk for developing heterotopic ossification.
Not a fit: Patients who do not have a history of inflammatory injuries or conditions leading to heterotopic ossification may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel therapeutic approach to prevent or treat heterotopic ossification in patients recovering from injuries.
How similar studies have performed: While the specific approach of targeting JMJD3 is novel, similar research has shown promise in understanding and potentially mitigating heterotopic ossification through molecular interventions.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GALLAGHER, KATHERINE ANN — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: GALLAGHER, KATHERINE ANN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Burn injury